Approval for Gleevec in record time, Brian Druker
Interviewee: Brian Druker. Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process. (DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Approval in record time)
And fortunately those phase 1 clinical trials were remarkably successful and then there was no looking back. Now Novartis at that point recognizing that they had a remarkably successful drug put resources behind this development like you couldn't imagine and accelerated the development of this drug through phase 2 and phase 3 and to market approval in record time. And so all the time that was lost while they were trying to make decisions about developing was caught up on the other end and they really deserve a huge amount of credit for once they realized they had something so successful for putting the major resources into its development that got it to patients as quickly as it did.
chronic myeloid leukemia,phase 1 clinical trials,brian druker,gleevec,time brian,location applications,market approval,major resources,dnai,record time,interviewee,cml,phase 3,novartis,phase 2,leukemia,genes,decisions,medicine
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
Brian Druker talks about how Gleevec has restored patients' hope for the future.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Brian Druker is a professor at Oregon Health Sciences University.
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
Brian Druker talks about Bud, the first patient restored to health by Gleevecâ¢.
Professor Charles Sawyer explains that EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S.